Highlights

  • Argent BioPharma (ASX:RGT) entered a global CannEpil licensing agreement announced in July 2026.
  • The CannEpil arrangement subsequently expanded to veterinary development and commercialisation.
  • A September licence added the Tollovir, Tollovid and NutraVir antiviral portfolio.
  • The December 2025 half-year recorded A$171,499 in customer revenue and a A$2.94 million loss.

Argent BioPharma Limited (ASX:RGT), an Australian biopharmaceutical business developing immune-focused medicines, delivery technologies and botanical products, has reshaped its portfolio through licensing and partnerships during 2026. The company’s CannEpil arrangements, expansion into veterinary applications and new antiviral rights give its latest disclosures a commercial as well as clinical dimension. At the time of writing on 19 October 2026, Argent BioPharma shares were trading at AUD 0.028, a gain of 3.70% during the day’s trading session. The company’s product development, contractual payments and funding requirements remain separate matters for review.

Company Business

Argent develops investigational pharmaceutical formulations and supports selected commercial supplement products. Its portfolio includes RGT-CA91980, a self-nano-emulsifying drug-delivery formulation being investigated in immune-related conditions, alongside early-stage NanoBodies and peptide research. These pharmaceutical programmes require further scientific and regulatory work; they should not be confused with approved medicines.

CannEpil is a separate investigational programme associated with drug-resistant epilepsy. Argent retains underlying intellectual property while its licensee undertakes agreed human and veterinary development and commercialisation activities. The business also operates botanical supplement platforms, including CimetrA, marketed as ArtemiC. Its infrastructure and development network includes Meta Medix activities in Slovenia and specialist manufacturing capabilities in Europe. The company distinguishes supplement sales from evidence of pharmaceutical efficacy.

Recent Development

In July 2026, Argent announced a global CannEpil licensing transaction described as a US$5.5 million deal. The company subsequently extended the licence to veterinary healthcare. In August, it reported the commencement of a US veterinary development programme and said the US Food and Drug Administration’s Center for Veterinary Medicine had established an Investigational New Animal Drug file for the programme. An INAD file facilitates investigational activity; it is not a marketing authorisation.

In September 2026, Argent announced an agreement for rights to the NLC antiviral portfolio, covering Tollovir, Tollovid and NutraVir. These additions broaden the company’s commercial and product mix, but each product’s regulatory position and applicable market remain distinct. In early October, Argent also announced execution of a loan facility agreement. The actual financing terms, available drawdowns and subsequent cash use are important when assessing the company’s liquidity position.

Other 2026 milestones included completion of the CannPal asset acquisition and an associated option over Neuvis technology, as well as a provisional US patent filing relating to its NanoBodies platform. Patent applications and acquired intellectual property can support research plans, although they do not establish a finished product or regulatory approval.

Financial Performance and Sector Context

For the six months ended 31 December 2025, Argent reported customer revenue of A$171,499, compared with A$4,283 in the corresponding half-year. It recorded an operating loss of A$2.98 million, versus A$10.14 million a year earlier. The after-tax loss was A$2.94 million compared with A$12.16 million. Administrative expenses were A$2.52 million, while research and development expenses were A$402,303.

The company lodged its FY26 annual report in August 2026. Across the biopharmaceutical sector, revenue from licensing, product sales and research activities can differ materially in timing and predictability. Clinical testing, intellectual property management and regulatory submissions require expenditure before any medicine can be sold under a pharmaceutical approval. For Argent, the distinction between existing supplement commerce, partner-led development and investigational drug work remains central to reading its accounts.

Risks to Consider

Argent faces clinical and regulatory uncertainty across its investigational programmes. Research findings may not translate into approvable therapies, and partner-led projects depend in part on counterparties meeting contractual and development commitments. Commercial receipt of licensing consideration may be conditional or staged. Expenses, access to capital, possible equity dilution, manufacturing compliance and changing product regulations are additional considerations. Veterinary and human development pathways involve different evidence standards and approvals.

What to Watch Next

Upcoming company disclosures may clarify CannEpil’s human and veterinary study milestones, progress under the antiviral licensing arrangement, and the status of NanoBodies and RGT-CA91980 research. Investors may also monitor receipts arising from licensing contracts, the impact of the loan facility and the next quarterly cash-flow report. These updates should help distinguish signed agreements from recognised revenue and cash received.

Key Insights

Argent’s 2026 activity centres on partnered CannEpil development, additional antiviral rights and a broader immune-science portfolio. Its latest cited half-year figures show rising customer revenue from a low base alongside a continuing net loss. Financial reporting, partner execution, cash availability and the regulatory progress of individual programmes remain the key measurable developments.